Controversial disease dropped from Prozac product informationBMJ 2004; 328 doi: http://dx.doi.org/10.1136/bmj.328.7436.365 (Published 12 February 2004) Cite this as: BMJ 2004;328:365
- Ray Moynihan
- Washington, DC
The drug manufacturer Lilly has been forced to drop one of the disorders it had previously listed for its antidepressant drug fluoxetine (Prozac), following a finding by the European drug regulator that the condition was not a well-established disease entity.
Some health researchers welcomed the regulator's decision, saying premenstrual dysphoric disorder (PMDD), which was only recently described, was an invented illness and a strong example of the medicalisation of ordinary life.
“I think it's a wonderful decision” says Paula Caplan, a psychologist adjunct and professor at Brown University, Rhode Island. “This kind of scrutiny of the science or …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial